A Dose Blocked-randomized, Double-blind, Placebo Controlled, Single and Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamics and Food Effect of LC51-0255
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2017
At a glance
- Drugs LC51 0255 (Primary)
- Indications Inflammation
- Focus Adverse reactions
- Sponsors LG Chem
- 16 Oct 2017 Status changed from active, no longer recruiting to recruiting.
- 16 Jul 2017 Planned End Date changed from 31 Oct 2018 to 30 Nov 2018.
- 16 Jul 2017 Planned primary completion date changed from 31 Aug 2018 to 31 Jul 2018.